Products with Anti-osteoclastogenesis bioactivity
| Cat.No. | Product Name |
|---|---|
| BCN3193 | Bavachalcone |
| 1. Bavachalcone has antibiotic or anticancer activities. 2. Bavachalcone may be useful as a therapeutic drug for bone resorption-associated diseases. 3. Bavachalcone can protect the endothelial function by increasing AMPK activity and MnSOD expression and reducing mitochondrial oxidative stress. | |
| BCN3464 | 2''-O-Rhamnosylicariside II |
| 1.2"-O-Rhamnosylicariside II shows potent inhibitory activities on osteoclast-like cell formation at a concentration of 2 uM without toxic effects. 2. 2″-O-Rhamnosylicariside II shows potent antioxidant activity, with IC50 values of 11.5 ug/mL and 90.5 uM. | |
| BCN3724 | Alpha-Tocotrienol |
| 1. Alpha-Tocotrienol can exert anti-apoptotic neuroprotective action independently of its antioxidant property. 2. Alpha-Tocotrienol inhibits osteoclastic bone resorption by suppressing RANKL expression and signaling and bone resorbing activity. 3. Alpha-Tocotrienol supplementation counteracts the lipid peroxidation but not the barrier perturbation in the stratum corneum (SC) induced by 10% benzoyl peroxide (BPO). | |
| BCN3858 | Kinsenoside |
| 1. Kinsenoside could be useful for repairing beta cells in pancreatic islet injury as well as improving its function, it could promote the glucose tolerance of acute glucose increase in both diabetic and normal healthy rats. 2. Kinsenoside shows significant antihepatotoxic activity. 3. Kinsenoside inhibits osteoclastogenesis from macrophages by attenuating RANKL-induced NF-κB and NFATc1 activities, which in turn, prevents bone loss from OVX mice. 4. Kinsenoside can inhibit the production of inflammatory mediators and enhanc anti-inflammatory cytokine generation, therefore, kinsenoside can alleviate acute inflammatory hazards. | |
| BCN3869 | Alliin |
| 1. Alliin protects against Lipopolysaccharides (LPS)-induced acute lung injury (ALI) by activating PPARγ, which subsequently inhibits LPS-induced NF-κB activation and inflammatory response, alliin may be used as an anti-inflammatory agent in the treatment of ALI. 2. Alliin has antiglycating potential , it offers protection against glucose or methyglyoxal induced glycation of superoxide dismutase. 3. Alliin has a good antiglycating effect and hence is expected to have therapeutic potential in the prevention of glycation-mediated diabetic complications. 4. Alliin and sabinene have detectable levels of antimicrobial activity. 5. Alliin has an inhibitory effect in osteoclasteogenesis with a dose-dependent manner via blocking the c-Fos-NFATc1 signaling pathway, it could be a potential therapeutic agent in the treatment of osteoporosis. | |
